Evidence Ratings: Difference between revisions

From WikiMSK

No edit summary
 
(25 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Strength-of-Recommendation Taxonomy (SORT)==
{{partial}}
Read about the levels of evidence here.


Code Definition
==ASIPP==
A Consistent, good-quality patient-oriented evidence *
ASIPP evidence ratings are preferred when assessing evidence in WikiMSK.
B Inconsistent or limited-quality patient-oriented evidence *
C Consensus, disease-oriented evidence *, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention, or screening
* Patient-oriented evidence measures outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, and quality of life. Disease-oriented evidence measures immediate, physiologic, or surrogate end points that may or may not reflect improvements in patient outcomes (e.g. blood pressure, blood chemistry, physiologic function, pathologic findings).


==Grading of Recommendations Assessment, Development and Evaluation (GRADE)==
{| class="wikitable"
|+ Modified grading of qualitative evidence with best evidence synthesis for therapeutic interventions
|-
!colspan="2"  style="text-align: center;|Therapy/Prevention/Etiology/Harm
|-
! Level I
| Multiple relevant high quality randomized controlled trials
|-
! Level II
| At least one relevant high quality randomized controlled trial or multiple relevant moderate or low quality randomized controlled trials
|-
! Level III
| At least one relevant moderate or low quality randomized controlled trial study<br/>or<br/>At least one relevant high quality non-randomized trial or observational study with multiple moderate<br/>or<br/>multiple moderate or low quality observational studies
|-
! Level IV
| Multiple moderate or low quality relevant observational studies
|-
! Level V
| Opinion or consensus of large group of clinicians and/or scientists.
|-
|}


Code Quality of Evidence Definition
{| class="wikitable"
A High
|+ Modified grading of qualitative evidence with best evidence synthesis for diagnostic accuracy
Further research is very unlikely to change our confidence in the estimate of effect.
|-
!colspan="2"  style="text-align: center;|Diagnosis
|-
! Level I
| Multiple high quality diagnostic accuracy studies
|-
! Level II
| At least one high quality diagnostic accuracy study or multiple moderate or low quality diagnostic accuracy studies
|-
! Level III
| At least one moderate quality diagnostic accuracy study in addition to low quality studies
|-
! Level IV
| Multiple relevant low quality diagnostic accuracy studies
|-
! Level V
| Opinion or consensus of large group of clinicians and/or scientists.
|-
|}
 
 
[[Media:ASIPP A Modified Approach to Grading of Evidence.pdf|Based on ASIPP criteria]]<ref>Manchikanti L, Falco FJ, Benyamin RM, Kaye AD, Boswell MV, Hirsch JA. A modified approach to grading of evidence. Pain Physician. 2014;17(3):E319-E325.</ref>
Template: {{t|ASIPP|rating}}
 
==SORT==
Strength-of-Recommendation Taxonomy
{| class="wikitable"
!Code
!Definition
|-
|A
|Consistent, good-quality patient-oriented evidence
|-
|B
|Inconsistent or limited-quality patient-oriented evidence
|-
|C
|Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention, or screening
|}
 
'''Patient-oriented evidence''' measures outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, and quality of life.
 
'''Disease-oriented evidence''' measures immediate, physiologic, or surrogate end points that may or may not reflect improvements in patient outcomes (e.g. blood pressure, blood chemistry, physiologic function, pathologic findings).
 
Template: {{t|SORT|rating}}
 
==GRADE==
Grading of Recommendations Assessment, Development and Evaluation (GRADE)
{| class="wikitable"
!Code
!Quality of Evidence
!Definition
|-
|A
|High
|Further research is very unlikely to change our confidence in the estimate of effect.


Several high-quality studies with consistent results
Several high-quality studies with consistent results
In special cases: one large, high-quality multi-centre trial
In special cases: one large, high-quality multi-centre trial
B Moderate
|-
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
|B
|Moderate
|Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.


One high-quality study
One high-quality study
Several studies with some limitations
Several studies with some limitations
C Low
|-
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
|C
|Low
|Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.


One or more studies with severe limitations
One or more studies with severe limitations
D Very Low
|-
Any estimate of effect is very uncertain.
|D
|Very Low
|Any estimate of effect is very uncertain
|-
|Expert Opinion
|No direct research evidence
|One or more studies with very severe limitations
|}
 


Expert opinion
No direct research evidence
One or more studies with very severe limitations
Source: GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group 2007 1 (modified by the EBM Guidelines Editorial Team)
Source: GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group 2007 1 (modified by the EBM Guidelines Editorial Team)


==Centre for Evidence-Based Medicine==
 
Oxford
Template: {{t|GRADE|rating}}
==CEBM==
Centre for Evidence-Based Medicine, Oxford
For the most up-to-date levels of evidence, see www.cebm.net/?o=1025
For the most up-to-date levels of evidence, see www.cebm.net/?o=1025


Therapy/Prevention/Etiology/Harm:
{| class="wikitable"
1a: Systematic reviews (with homogeneity ) of randomized controlled trials
|-
1a-: Systematic review of randomized trials displaying worrisome heterogeneity
! colspan="2" style="text-alig:center;" |Therapy/Prevention/Etiology/Harm
1b: Individual randomized controlled trials (with narrow confidence interval)
|-
1b-: Individual randomized controlled trials (with a wide confidence interval)
!1a
1c: All or none randomized controlled trials
|Systematic reviews (with homogeneity ) of randomized controlled trials
2a: Systematic reviews (with homogeneity) of cohort studies
|-
2a-: Systematic reviews of cohort studies displaying worrisome heterogeneity
!1a-
2b: Individual cohort study or low quality randomized controlled trials (<80% follow-up)
|Systematic review of randomized trials displaying worrisome heterogeneity
2b-: Individual cohort study or low quality randomized controlled trials (<80% follow-up / wide confidence interval)
|-
2c: 'Outcomes' Research; ecological studies
!1b
3a: Systematic review (with homogeneity) of case-control studies
|Individual randomized controlled trials (with narrow confidence interval)
3a-: Systematic review of case-control studies with worrisome heterogeneity
|-
3b: Individual case-control study
!1b-
4: Case-series (and poor quality cohort and case-control studies)
|Individual randomized controlled trials (with a wide confidence interval)
5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
|-
Diagnosis:
!1c
1a: Systematic review (with homogeneity) of Level 1 diagnostic studies; or a clinical rule validated on a test set.
|All or none randomized controlled trials
1a-: Systematic review of Level 1 diagnostic studies displaying worrisome heterogeneity
|-
1b: Independent blind comparison of an appropriate spectrum of consecutive patients, all of whom have undergone both the diagnostic test and the reference standard; or a clinical decision rule not validated on a second set of patients
!2a
1c: Absolute SpPins And SnNouts (An Absolute SpPin is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An Absolute SnNout is a diagnostic finding whose Sensitivity is so high that a Negative result rules-out the diagnosis).
|Systematic reviews (with homogeneity) of cohort studies
2a: Systematic review (with homogeneity) of Level >2 diagnostic studies
|-
2a-: Systematic review of Level >2 diagnostic studies displaying worrisome heterogeneity
!2a-
2b: Any of: 1)independent blind or objective comparison; 2)study performed in a set of non-consecutive patients, or confined to a narrow spectrum of study individuals (or both) all of whom have undergone both the diagnostic test and the reference standard; 3) a diagnostic clinical rule not validated in a test set.
|Systematic reviews of cohort studies displaying worrisome heterogeneity
3a: Systematic review (with homogeneity) of case-control studies
|-
3a-: Systematic review of case-control studies displaying worrisome heterogeneity
!2b
4: Any of: 1)reference standard was unobjective, unblinded or not independent; 2) positive and negative tests were verified using separate reference standards; 3) study was performed in an inappropriate spectrum of patients.
|Individual cohort study or low quality randomized controlled trials (<80% follow-up)
5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
|-
Prognosis:
!2b-
1a: Systematic review (with homogeneity) of inception cohort studies; or a clinical rule validated on a test set.
|Individual cohort study or low quality randomized controlled trials (<80% follow-up / wide confidence interval)
1a-: Systematic review of inception cohort studies displaying worrisome heterogeneity
|-
1b: Individual inception cohort study with > 80% follow-up; or a clinical rule not validated on a second set of patients
!2c
1c: All or none case-series
|'Outcomes' Research; ecological studies
2a: Systematic review (with homogeneity) of either retrospective cohort studies or untreated control groups in RCTs.
|-
2a-: Systematic review of either retrospective cohort studies or untreated control groups in RCTs displaying worrisome heterogeneity
!3a
2b: Retrospective cohort study or follow-up of untreated control patients in an RCT; or clinical rule not validated in a test set.
|Systematic review (with homogeneity) of case-control studies
2c: 'Outcomes' research
|-
4: Case-series (and poor quality prognostic cohort studies)
!3a-
5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
|Systematic review of case-control studies with worrisome heterogeneity
|-
!3b
|Individual case-control study
|-
!4
|Case-series (and poor quality cohort and case-control studies)
|-
!5
|Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
|-
|}
 
{| class="wikitable"
|-
! colspan="2" style="text-align:center;" |Diagnosis
|-
!1a
|Systematic review (with homogeneity) of Level 1 diagnostic studies; or a clinical rule validated on a test set.
|-
!1a-
|Systematic review of Level 1 diagnostic studies displaying worrisome heterogeneity
|-
!1b
|Independent blind comparison of an appropriate spectrum of consecutive patients, all of whom have undergone both the diagnostic test and the reference standard; or a clinical decision rule not validated on a second set of patients
|-
!1c
|Absolute SpPins And SnNouts (An Absolute SpPin is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An Absolute SnNout is a diagnostic finding whose Sensitivity is so high that a Negative result rules-out the diagnosis).
|-
!2a
|Systematic review (with homogeneity) of Level >2 diagnostic studies
|-
!2a
|Systematic review of Level >2 diagnostic studies displaying worrisome heterogeneity
|-
!2b
|Any of 1)independent blind or objective comparison; 2)study performed in a set of non-consecutive patients, or confined to a narrow spectrum of study individuals (or both) all of whom have undergone both the diagnostic test and the reference standard; 3) a diagnostic clinical rule not validated in a test set.
|-
!3a
|Systematic review (with homogeneity) of case-control studies
|-
!3a
|Systematic review of case-control studies displaying worrisome heterogeneity
|-
!4
|Any of 1)reference standard was unobjective, unblinded or not independent; 2) positive and negative tests were verified using separate reference standards; 3) study was performed in an inappropriate spectrum of patients.
|-
!5
|Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
|-
|}
 
{| class="wikitable"
|-
! colspan="2" style="text-align:center;" |Prognosis
|-
|-
!1a
|Systematic review (with homogeneity) of inception cohort studies; or a clinical rule validated on a test set.
|-
!1a-
|Systematic review of inception cohort studies displaying worrisome heterogeneity
|-
!1b
|Individual inception cohort study with > 80% follow-up; or a clinical rule not validated on a second set of patients
|-
!1c
|All or none case-series
|-
!2a
|Systematic review (with homogeneity) of either retrospective cohort studies or untreated control groups in RCTs.
|-
!2a-
|Systematic review of either retrospective cohort studies or untreated control groups in RCTs displaying worrisome heterogeneity
|-
!2b
|Retrospective cohort study or follow-up of untreated control patients in an RCT; or clinical rule not validated in a test set.
|-
!2c
|'Outcomes' research
|-
!4
|Case-series (and poor quality prognostic cohort studies)
|-
!5
|Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
|-
|}
 
Template| {{t|CEBM|rating}}


==Practice Guidelines (various)==
==Practice Guidelines (various)==
Key to interpretation of practice guidelines
Key to interpretation of practice guidelines
Agency for Healthcare Research and Quality:
{| class="wikitable"
A: There is good research-based evidence to support the recommendation.
! colspan="2" |Agency for Healthcare Research and Quality
B: There is fair research-based evidence to support the recommendation.
|-
C: The recommendation is based on expert opinion and panel consensus.
|A
X: There is evidence of harm from this intervention.
|There is good research-based evidence to support the recommendation
USPSTF Guide to Clinical Preventive Services:
|-
A: There is good evidence to support the recommendation that the condition be specifically considered in a periodic health examination.
|B
B: There is fair evidence to support the recommendation that the condition be specifically considered in a periodic health examination.
|There is fair research-based evidence to support the recommendation.
C: There is insufficient evidence to recommend for or against the inclusion of the condition in a periodic health examination, but recommendations may be made on other grounds.
|-
D: There is fair evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.
|C
E: There is good evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.
| The recommendation is based on expert opinion and panel consensus
University of Michigan Practice Guideline:
|-
A: Randomized controlled trials.
|X
B: Controlled trials, no randomization.
|There is evidence of harm from this intervention
C: Observational trials.
|}
D: Opinion of the expert panel.
{| class="wikitable"
Other guidelines:
! colspan="2" |USPSTF Guide to Clinical Preventive Services
A: There is good research-based evidence to support the recommendation.
|-
B: There is fair research-based evidence to support the recommendation.
|A
C: The recommendation is based on expert opinion and panel consensus.
|There is good evidence to support the recommendation that the condition be specifically considered in a periodic health examination
X: There is evidence that the intervention is harmful.
|-
|B
|There is fair evidence to support the recommendation that the condition be specifically considered in a periodic health examination
|-
|C
|There is insufficient evidence to recommend for or against the inclusion of the condition in a periodic health examination, but recommendations may be made on other grounds
|-
|D
|There is fair evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination
|-
|E
|There is good evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.
|}
{| class="wikitable"
! colspan="2" |University of Michigan Practice Guideline
|-
|A
|Randomized controlled trials
|-
|B
|Controlled trials, no randomization
|-
|C
|Observational trials
|-
|D
|Opinion of the expert panel
|}
{| class="wikitable"
! colspan="2" |Other guidelines
|-
|A
|There is good research-based evidence to support the recommendation
|-
|B
|There is fair research-based evidence to support the recommendation
|-
|C
| The recommendation is based on expert opinion and panel consensus
|-
|X
|There is evidence that the intervention is harmful
|}
 
==References==
[[Category:Partially complete articles]]
[[Category:Evidence Based Medicine]]
<references />

Latest revision as of 06:55, 21 May 2021

This article is still missing information.

Read about the levels of evidence here.

ASIPP

ASIPP evidence ratings are preferred when assessing evidence in WikiMSK.

Modified grading of qualitative evidence with best evidence synthesis for therapeutic interventions
Therapy/Prevention/Etiology/Harm
Level I Multiple relevant high quality randomized controlled trials
Level II At least one relevant high quality randomized controlled trial or multiple relevant moderate or low quality randomized controlled trials
Level III At least one relevant moderate or low quality randomized controlled trial study
or
At least one relevant high quality non-randomized trial or observational study with multiple moderate
or
multiple moderate or low quality observational studies
Level IV Multiple moderate or low quality relevant observational studies
Level V Opinion or consensus of large group of clinicians and/or scientists.
Modified grading of qualitative evidence with best evidence synthesis for diagnostic accuracy
Diagnosis
Level I Multiple high quality diagnostic accuracy studies
Level II At least one high quality diagnostic accuracy study or multiple moderate or low quality diagnostic accuracy studies
Level III At least one moderate quality diagnostic accuracy study in addition to low quality studies
Level IV Multiple relevant low quality diagnostic accuracy studies
Level V Opinion or consensus of large group of clinicians and/or scientists.


Based on ASIPP criteria[1] Template: {{ASIPP|rating}}

SORT

Strength-of-Recommendation Taxonomy

Code Definition
A Consistent, good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention, or screening

Patient-oriented evidence measures outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, and quality of life.

Disease-oriented evidence measures immediate, physiologic, or surrogate end points that may or may not reflect improvements in patient outcomes (e.g. blood pressure, blood chemistry, physiologic function, pathologic findings).

Template: {{SORT|rating}}

GRADE

Grading of Recommendations Assessment, Development and Evaluation (GRADE)

Code Quality of Evidence Definition
A High Further research is very unlikely to change our confidence in the estimate of effect.

Several high-quality studies with consistent results

In special cases: one large, high-quality multi-centre trial

B Moderate Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

One high-quality study

Several studies with some limitations

C Low Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

One or more studies with severe limitations

D Very Low Any estimate of effect is very uncertain
Expert Opinion No direct research evidence One or more studies with very severe limitations


Source: GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group 2007 1 (modified by the EBM Guidelines Editorial Team)


Template: {{GRADE|rating}}

CEBM

Centre for Evidence-Based Medicine, Oxford For the most up-to-date levels of evidence, see www.cebm.net/?o=1025

Therapy/Prevention/Etiology/Harm
1a Systematic reviews (with homogeneity ) of randomized controlled trials
1a- Systematic review of randomized trials displaying worrisome heterogeneity
1b Individual randomized controlled trials (with narrow confidence interval)
1b- Individual randomized controlled trials (with a wide confidence interval)
1c All or none randomized controlled trials
2a Systematic reviews (with homogeneity) of cohort studies
2a- Systematic reviews of cohort studies displaying worrisome heterogeneity
2b Individual cohort study or low quality randomized controlled trials (<80% follow-up)
2b- Individual cohort study or low quality randomized controlled trials (<80% follow-up / wide confidence interval)
2c 'Outcomes' Research; ecological studies
3a Systematic review (with homogeneity) of case-control studies
3a- Systematic review of case-control studies with worrisome heterogeneity
3b Individual case-control study
4 Case-series (and poor quality cohort and case-control studies)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
Diagnosis
1a Systematic review (with homogeneity) of Level 1 diagnostic studies; or a clinical rule validated on a test set.
1a- Systematic review of Level 1 diagnostic studies displaying worrisome heterogeneity
1b Independent blind comparison of an appropriate spectrum of consecutive patients, all of whom have undergone both the diagnostic test and the reference standard; or a clinical decision rule not validated on a second set of patients
1c Absolute SpPins And SnNouts (An Absolute SpPin is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An Absolute SnNout is a diagnostic finding whose Sensitivity is so high that a Negative result rules-out the diagnosis).
2a Systematic review (with homogeneity) of Level >2 diagnostic studies
2a Systematic review of Level >2 diagnostic studies displaying worrisome heterogeneity
2b Any of 1)independent blind or objective comparison; 2)study performed in a set of non-consecutive patients, or confined to a narrow spectrum of study individuals (or both) all of whom have undergone both the diagnostic test and the reference standard; 3) a diagnostic clinical rule not validated in a test set.
3a Systematic review (with homogeneity) of case-control studies
3a Systematic review of case-control studies displaying worrisome heterogeneity
4 Any of 1)reference standard was unobjective, unblinded or not independent; 2) positive and negative tests were verified using separate reference standards; 3) study was performed in an inappropriate spectrum of patients.
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'
Prognosis
1a Systematic review (with homogeneity) of inception cohort studies; or a clinical rule validated on a test set.
1a- Systematic review of inception cohort studies displaying worrisome heterogeneity
1b Individual inception cohort study with > 80% follow-up; or a clinical rule not validated on a second set of patients
1c All or none case-series
2a Systematic review (with homogeneity) of either retrospective cohort studies or untreated control groups in RCTs.
2a- Systematic review of either retrospective cohort studies or untreated control groups in RCTs displaying worrisome heterogeneity
2b Retrospective cohort study or follow-up of untreated control patients in an RCT; or clinical rule not validated in a test set.
2c 'Outcomes' research
4 Case-series (and poor quality prognostic cohort studies)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or 'first principles'

Template| {{CEBM|rating}}

Practice Guidelines (various)

Key to interpretation of practice guidelines

Agency for Healthcare Research and Quality
A There is good research-based evidence to support the recommendation
B There is fair research-based evidence to support the recommendation.
C The recommendation is based on expert opinion and panel consensus
X There is evidence of harm from this intervention
USPSTF Guide to Clinical Preventive Services
A There is good evidence to support the recommendation that the condition be specifically considered in a periodic health examination
B There is fair evidence to support the recommendation that the condition be specifically considered in a periodic health examination
C There is insufficient evidence to recommend for or against the inclusion of the condition in a periodic health examination, but recommendations may be made on other grounds
D There is fair evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination
E There is good evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.
University of Michigan Practice Guideline
A Randomized controlled trials
B Controlled trials, no randomization
C Observational trials
D Opinion of the expert panel
Other guidelines
A There is good research-based evidence to support the recommendation
B There is fair research-based evidence to support the recommendation
C The recommendation is based on expert opinion and panel consensus
X There is evidence that the intervention is harmful

References

  1. Manchikanti L, Falco FJ, Benyamin RM, Kaye AD, Boswell MV, Hirsch JA. A modified approach to grading of evidence. Pain Physician. 2014;17(3):E319-E325.